Introduction
============

Systemic-onset juvenile idiopathic arthritis (SOJIA) is a severe and distinctive type of juvenile arthritis ([@b1-etm-0-0-7174]). The pathophysiology of systemic manifestations of SOJIA appears to be associated with continuous activation of innate immune pathways, resulting in dysregulated production of proinflammatory cytokines ([@b2-etm-0-0-7174]). For example, interleukin (IL)-1β ([@b3-etm-0-0-7174],[@b4-etm-0-0-7174]) and IL-6 ([@b5-etm-0-0-7174]) have been indicated to be important cytokines in the pathogenesis of SOJIA. Therefore, targeting IL-1 and IL-6 has become a treatment strategy for SOJIA ([@b6-etm-0-0-7174],[@b7-etm-0-0-7174]).

Tacrolimus (TAC) is a relatively novel immunosuppressive drug, which inhibits the transcription of the early activation genes of IL-2 and suppresses the production of tumor necrosis factor (TNF)-α, IL-1β and IL-6 through T cell activation ([@b8-etm-0-0-7174],[@b9-etm-0-0-7174]). In addition to being used during transplantation, TAC has also been used without serious adverse effects for treating refractory nephrotic syndrome ([@b10-etm-0-0-7174],[@b11-etm-0-0-7174]), lupus nephritis ([@b12-etm-0-0-7174]), and rheumatoid arthritis ([@b8-etm-0-0-7174],[@b9-etm-0-0-7174]). However, few studies have reported the use of treatment with TAC in patients with SOJIA. The aim of the current study was to investigate the effect of TAC on SOJIA.

Patients and methods
====================

### Patients

The current data were obtained retrospectively from medical records of patients diagnosed with SOJIA. All patients were under 18 years old and received TAC treatment at the Children\'s Hospital of Fudan University (Shanghai, China) between January 2015 and January 2018.

### Patient characteristics and outcomes

Data were collected from the beginning of TAC treatment for 12 months, with the 12-month endpoint defined as the last follow-up. Clinical characteristics including sex, age, duration of the disease, TAC dose, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), hemoglobin (Hb), platelet (PLT) and white blood cell (WB) levels, prednisolone (PDN) dose and interleukin-6 (IL-6) expression at the beginning of TAC treatment (0 months) and following treatment with TAC for 6 months and 12 months were obtained from medical records retrospectively.

### Statistical analysis

Data are presented as the mean ± standard error. Statistical analyses were performed using the General Linear Model for repeated measurement. P\<0.05 was considered to indicate a statistically significant difference. The statistical analysis was performed using SPSS software (version 13.0; SPSS, Inc., Chicago, IL, USA).

Results
=======

### Summary of clinical characteristics

Clinical characteristics are summarized in [Table I](#tI-etm-0-0-7174){ref-type="table"}. A total of 6 Chinese patients with SOJIA, including 3 males and 3 females from Children\'s Hospital of Fudan University, were included for studying the effect of TAC on SOJIA. Patient ages ranged from 5.5 to 14.0 years old (mean, 10.8±3.0 years), and the duration of disease ranged from 1.1 to 5.0 years. During follow-up time, TAC doses were 1.0--3.0 mg/day. The baseline characteristics of the patients were: ESR, 67.8±18.7 mm/h; CRP, 128.0±38.9 mg/l; Hb, 108.7±13.7 g/l; PLT, 416.8±90.1×10^9^/l; WB, 26.0±10.2×10^9^/l; PDN dose, 49.0±17.1 mg/day.

### Changes in ESR and CRP level following treatment with TAC

ESR and CRP level were significantly lower at 6 and 12 months compared with 0 months (all P\<0.05; [Fig. 1](#f1-etm-0-0-7174){ref-type="fig"}). These results indicated that TAC could significantly downregulate the high ESR and CRP level in SOJIA.

### Changes in Hb, PLT and WB levels following treatment with TAC

Hb level significantly increased at 6 months of treatment with TAC compared with the baseline level (P\<0.05; [Fig. 2A and B](#f2-etm-0-0-7174){ref-type="fig"}). However, following treatment with TAC for 12 months, the Hb level decreased compared with the value at 6 months (P\<0.05). PLT and WB levels significantly decreased after 6 and 12 months of treatment with TAC compared with baseline (all P\<0.05; [Fig. 2C-F](#f2-etm-0-0-7174){ref-type="fig"}). These results indicated that administration of TAC significantly decreased the levels of PLT and WB in patients with SOJIA. However, the level of Hb increased at 6 months, followed by a decrease at 12 months of treatment.

### Changes in PDN dose following treatment with TAC

Following treatment with TAC for 6 and 12 months, PDN dose was decreased compared with the baseline (P\<0.05; [Fig. 3](#f3-etm-0-0-7174){ref-type="fig"}), indicating that treatment with TAC reduced the dose of PDN required for the treatment of patients with SOJIA.

### Changes in the expression levels of IL-6 following treatment with TAC

Following treatment with TAC for 12 months, the expression levels of IL-6 decreased significantly compared with the baseline level ([Table II](#tII-etm-0-0-7174){ref-type="table"}). These results indicated that administration of TAC significantly decreased the expression levels of IL-6 in patients with SOJIA.

Discussion
==========

A proportion of patients with SOJIA continue to require long-term corticosteroid therapy for disease control. However, repeated and prolonged steroid therapy increases the risk of obesity, cushingoid appearance, hypertension, growth retardation, osteoporosis, infections and psychological problems ([@b13-etm-0-0-7174]). Therefore, a safe and effective therapeutic strategy for controlling SOJIA is required ([@b14-etm-0-0-7174]).

Previous studies have identified the importance of suppressing the pathogenic effects of IL-6 and other proinflammatory cytokines in treating SOJIA ([@b14-etm-0-0-7174]--[@b16-etm-0-0-7174]). TAC effectively suppresses the production of TNF-α, IL-1β and IL-6 through T cell activation ([@b9-etm-0-0-7174],[@b12-etm-0-0-7174]), and has been successfully used without serious adverse effects to treat rheumatoid arthritis in adults and the elderly patients ([@b8-etm-0-0-7174],[@b9-etm-0-0-7174]). Therefore, it was hypothesized that TAC may be safe and effective to treat SOJIA.

In the current study, it was identified that TAC could significantly downregulate the high ESR, CRP, PLT and WB levels in patients with SOJIA. The dose of the concomitantly administered PDN was gradually reduced during the 12 months of treatment with TAC. The current study indicated that TAC may reduce the required PDN dose and may be an effective treatment strategy for SOJIA.

The mechanism by which TAC effectively ameliorates SOJIA requires further investigation. Previously, the successful use of recombinant homolog of IL-6 receptor antagonist (IL-6Ra), which competitively inhibits binding of IL-6 to the IL-6 receptor, has been reported in the treatment of SOJIA ([@b14-etm-0-0-7174],[@b17-etm-0-0-7174]). The studies verified that IL-6 is a therapeutic target in SOJIA ([@b14-etm-0-0-7174],[@b17-etm-0-0-7174]). In the current study, it was identified that TAC effectively suppresses IL-6 production; therefore, this may be the mechanism by which TAC exerts its therapeutic effects in SOJIA.

Furthermore, previous studies have reported the use of TAC for the treatment of patients with SOJIA. Shimizu *et al* ([@b18-etm-0-0-7174]) reported a case of a 6-year-old Japanese female who presented with a 6-month history of polyarthritis and was diagnosed with poly-JIA. This study identified TAC as a potential alternative when treating patients with refractory polyarticular JIA ([@b18-etm-0-0-7174]). In addition, Tanaka *et al* ([@b19-etm-0-0-7174]) reported using TAC to treat difficult cases of SOJIA, including an 8.5-year-old Japanese male with a 6-year history of SOJIA, and a 5-year-old Japanese female with a 1.5-year history of refractory SOJIA. However, these studies both focused on Japanese children. To the best of our knowledge, this is the first study to report the treatment of SOJIA with TAC in Chinese children, including three males and three females, whose duration of disease ranged from 1.1 to 5.0 years.

In conclusion, TAC may be an effective treatment strategy for patients with SOJIA. However, the current study was performed at a single center. Therefore, further multicenter and prospective studies with a larger number of patients are required.
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![Alterations in ESR and CRP level following treatment with TAC. (A) ESR of each patient. (B) Mean ± SE values of ESR. (C) CRP levels of each patient. (D) Mean ± SE values of CRP levels. \*P\<0.05 vs.0 months. ESR, erythrocyte sedimentation rate; CRP, C reactive protein; TAC, tacrolimus; 0 months, data obtained prior to treatment with TAC; 6 months, data obtained at 6 months of treatment with TAC; 12 months, data obtained at 12 months of treatment with TAC.](etm-17-03-2305-g00){#f1-etm-0-0-7174}

![Changes in Hb, PLT and WB levels following treatment with TAC. (A) Alterations in Hb levels of each patient. (B) Mean ± SE values of Hb levels. (C) Alterations in PLT levels of each patient. (D) Mean ± SE values of PLT levels. (E) Alterations in WB levels of each patient. (F) Mean ± SE values of WB levels. \*P\<0.05 vs.0 months and ^\#^P\<0.05 vs. 6 months. TAC, tacrolimus; Hb, hemoglobin; PLT, platelet; WB, white blood cell; 0 months, data obtained prior to treatment with TAC; 6 months, data obtained at 6 months of treatment with TAC; 12 months, data obtained at 12 months of treatment with TAC.](etm-17-03-2305-g01){#f2-etm-0-0-7174}

![Changes in PDN dose following treatment with TAC. (A) Alterations in PDN dose administered to each patient. (B) Mean ± SE values of PDN dose. \*P\<0.05 vs.0 months and ^\#^P\<0.05 vs. 6 months. PDN, prednisolone; 0 months, data obtained prior to treatment with TAC; 6 months, data obtained at 6 months of treatment with TAC; 12 months, data obtained at 12 months of treatment with TAC; TAC, tacrolimus.](etm-17-03-2305-g02){#f3-etm-0-0-7174}

###### 

Summary of clinical characteristics.

                                         ESR, mm/h   CRP, mg/l                                               Hb, g/l      PLT, 10^9^/l                                          WB, 10^9^/l   PDN, mg/day                                                                                                                                                           
  ----------- ---- ---------- ---------- ----------- ------------------------------------------------------- ------------ ----------------------------------------------------- ------------- ------------- ------------ ---------------------------------------------------------- ----------- ------------------------------------------------------- ----------- -------------------------------------------------------
  1           M    13.0       2.0--3.0   68.0        12.0                                                    160.0        8.0                                                   117.0         125.0         433.0        242.0                                                      37.1        7.3                                                     60.0        2.5
  2           F    11.5       2.0--3.0   72.0        5.0                                                     119.0        8.0                                                   102.0         104.2         460.0        249.0                                                      37.0        8.3                                                     60.0        5.0
  3           M    11.0       2.0--3.0   78.0        4.0                                                     160.0        8.0                                                   117.0         124.0         319.0        316.0                                                      28.1        6.9                                                     60.0        0.0
  4           F    5.5        1.0--2.0   58.0        9.0                                                     67.0         8.0                                                   91.2          102.2         326.0        233.0                                                      10.7        6.2                                                     24.0        0.0
  5           F    9.5        1.0--2.0   38.0        3.0                                                     102.0        8.0                                                   127.0         138.0         560.0        364.0                                                      20.5        7.3                                                     30.0        0.0
  6           M    14.0       1.0--2.0   93.0        1.0                                                     160.0        8.0                                                   98.2          116.0         403.0        117.0                                                      22.5        5.5                                                     60.0        0.0
  Mean ± SD   --   10.8±3.0   --         67.8±18.7   5.7±4.1^[a](#tfn2-etm-0-0-7174){ref-type="table-fn"}^   128.0±38.9   8.0±0^[a](#tfn2-etm-0-0-7174){ref-type="table-fn"}^   108.7±13.7    118.2±13.6    416.8±90.1   253.5±84.0^[a](#tfn2-etm-0-0-7174){ref-type="table-fn"}^   26.0±10.2   6.9±1.0^[a](#tfn2-etm-0-0-7174){ref-type="table-fn"}^   49.0±17.1   1.3±2.1^[a](#tfn2-etm-0-0-7174){ref-type="table-fn"}^

TAC, tacrolimus; baseline, measurement prior to treatment with TAC; last visit, measurement following treatment with TAC for 12 months; M, male; F, female; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; Hb, hemoglobin; PLT, platelet; WB, white blood cell; PDN, prednisolone; SD, standard deviation.

P\<0.05 vs. baseline.

###### 

Alterations in IL-6 expression levels among the 6 patients.

              IL-6, pg/ml     
  ----------- --------------- ---------------------------------------------------------
  1           265.90          15.04
  2           50.00           8.70
  3           112.90          9.05
  4           \>1000.00       1.92
  5           198.00          9.13
  6           317.80          2.35
  Mean ± SD   324.10±345.23   7.70±4.91^[a](#tfn4-etm-0-0-7174){ref-type="table-fn"}^

IL-6, interleukin 6; TAC, tacrolimus; SD, standard deviation.

P\<0.05 vs. baseline.
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